How the Sickle Cell Guidelines Weigh Hydroxyurea and Transfusion

A good clinical guideline does not just hand you an answer; it shows its work. The American Society of Hematology 2020 guidelines on cerebrovascular disease in sickle cell disease do this by attaching two labels to every recommendation: how strong it is, and how certain the evidence behind it is. Once you learn to read those two labels together, the document stops looking like a list of instructions and starts looking like a transparent argument, with hydroxyurea and chronic transfusion landing in different places for reasons the panel spells out.

This piece appraises how that guideline is built.

Key points#

• ASH 2020 grades every recommendation on two separate axes: strength (strong or conditional) and certainty of evidence (high to very low).
• Annual transcranial Doppler (TCD) screening in children is a strong recommendation, because a positive result triggers an action that works.
• Chronic transfusion for children with abnormal TCD velocities rests on the STOP trial, which showed a large stroke-risk reduction.
• Hydroxyurea appears as a conditional option: as a switch after a year of transfusion in selected children (from the TWiTCH trial), or as the practical choice where transfusion is not reliably available.
• A conditional recommendation is an invitation to weigh individual circumstances, not a watered-down command.

Two dials, not one#

The panel used the GRADE framework, which deliberately keeps two things apart that everyday language tends to blur.

The first dial is the strength of the recommendation, and it hides in the verbs. When the guideline "recommends" something, that is a strong recommendation: the panel expects most patients in that situation to want it, so it can serve as a default. When it "suggests" something, that is a conditional recommendation: the balance of benefit and harm is closer, and the right call leans more on individual values, circumstances, and access.

The second dial is certainty of evidence, rated high, moderate, low, or very low. This is not asking whether an effect is real; it is asking how confident we can be in the size of that effect. Randomized trials usually start high and get marked down for issues like imprecision, indirectness, or risk of bias, while observational data usually starts low. The reason to keep the dials separate is that they can point different ways. A recommendation can be strong on moderate certainty, because strength also weighs harms, burden, and cost. And a recommendation can stay conditional even when a benefit looks plausible, because the evidence is narrow or the tradeoffs vary from patient to patient.

Screening earns its firm footing#

The steadiest ground in the whole document is transcranial Doppler screening. TCD ultrasound measures how fast blood moves through the large arteries at the base of the brain, and unusually high velocities flag children whose stroke risk is sharply elevated. For children aged 2 to 16 with HbSS or HbSβ0 thalassemia, the panel issued a strong recommendation for annual TCD screening on moderate-certainty evidence.

That strength is not about the test being clever. It is about what a positive result unlocks. The Stroke Prevention Trial in Sickle Cell Anemia (STOP), published in 1998, screened children with TCD and randomized those with abnormal velocities to regular transfusion or usual care. The transfusion arm cut the risk of a first stroke by roughly 90 percent, and the trial was halted early once that benefit was clear. Screening is worth a strong recommendation precisely because an effective action follows the result. A perfectly accurate test that led to nothing useful would not clear that bar.

Where the biology is similar but the direct trial evidence is thin, the labels shift accordingly. For rarer compound heterozygous genotypes with hemolysis in the HbSS range, the screening recommendation softens to conditional on very low certainty. The panel names the gap rather than papering over it.

The same question, answered by two trials#

Once a child's velocities are abnormal, the first move is well supported. For a child with abnormal TCD in a well-resourced setting, the panel strongly recommends starting regular transfusion, aiming to hold HbS below a set threshold, for at least a year. That is STOP read straight across: a randomized result, a large effect, moderate certainty, a strong recommendation.

The harder question is what to do after that first year, and here a second trial does the work. TWiTCH (Transcranial Doppler With Transfusions Changing to Hydroxyurea), published in 2016, enrolled children who already had at least a year of transfusion behind them and who did not show severe vasculopathy on imaging. It tested whether switching to maximum-tolerated-dose hydroxyurea could hold TCD velocities as well as staying on transfusion, and it was built as a non-inferiority trial. In that carefully bounded group, hydroxyurea held its own.

The guideline mirrors both the promise and the fence around that result. It conditionally suggests that, after at least a year of transfusion, hydroxyurea at maximum tolerated dose may take over, but only once imaging has ruled out significant vasculopathy or silent cerebral infarcts, echoing who TWiTCH actually enrolled. The certainty is lower and the recommendation is conditional because the trial answered a narrow question in a selected population, and stretching it past those edges is the exact indirectness GRADE is designed to penalize.

Why the setting rewrites the advice#

One feature that is easy to miss is that the guideline writes different recommendations for different resource settings. That is not indecision. A recommendation is a judgment about action, and the menu of possible actions is not the same everywhere. A regular transfusion program assumes a dependable blood supply, monitoring for iron overload, chelation, and staffing that many regions cannot count on.

So for children with abnormal TCD in low- and middle-income settings without reliable transfusion access, the panel suggests hydroxyurea at a fixed dose of at least 20 mg/kg per day, or maximum tolerated dose, as a conditional recommendation on low-certainty evidence. The comparison here is telling: it is not hydroxyurea against a fully resourced transfusion program, but hydroxyurea against having almost no effective prevention at all. Letting context reshape the recommendation is a mark of careful guideline construction, not a contradiction.

Reading the labels for what they say#

The thread running through all of this is that strength and certainty carry real information, and collapsing them into a single verdict throws that information away. A conditional suggestion is an open door to weigh values, imaging findings, and access; it is not a timid version of an order. A strong recommendation signals the panel expects it to hold across most patients in that situation.

None of this decides your care, which turns on genotype, prior imaging, transfusion history, and access, and belongs in a conversation with a treating hematologist. What the ASH 2020 document does well is model disciplined reasoning: name the trial, grade the certainty, state the strength, and let the setting shape the action. Read that way, its labels are not decoration; they are the load-bearing parts of the argument.